STC XXXX
Alternative Names: STC-XXXXLatest Information Update: 18 Aug 2021
At a glance
- Originator Brenus Pharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Tumour cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Lung cancer; Malignant melanoma
Most Recent Events
- 05 Aug 2021 STC XXXX is available for licensing as of 05 Aug 2021. https://brenus-pharma.com/#ourvision (Brenus Pharma website, August 2021)
- 05 Aug 2021 Brenus Pharma has a patent protection for a scalable technology of stimulated tumour cells (Brenus Pharma website, August 2021)
- 05 Aug 2021 Brenus Pharma has patents pending for therapeutic cancer vaccines worldwide